Building the Industry’s Most Advanced Modelling Engine

For the past ten years, the industry has seen an increased demand to determine fair market value of CRO and other clinical trial service providers.

Not only do these costs account for the largest portion of the direct clinical trial cost at the onset of the trial, but the change orders associated with these cost categories are the main culprits for significant cost swings during the trial execution.

While total negotiated cost is of importance during planning and budgeting exercises or CRO negotiation, the estimation of actual activity- completed costs and accurate time distribution of cost throughout the lifecycle of the trial (reforecasting), are equally critical for financial planning and reporting and for overall study risk management.